CN1943579A - Use of asiatic acid in preparing medicine - Google Patents
Use of asiatic acid in preparing medicine Download PDFInfo
- Publication number
- CN1943579A CN1943579A CN 200610122561 CN200610122561A CN1943579A CN 1943579 A CN1943579 A CN 1943579A CN 200610122561 CN200610122561 CN 200610122561 CN 200610122561 A CN200610122561 A CN 200610122561A CN 1943579 A CN1943579 A CN 1943579A
- Authority
- CN
- China
- Prior art keywords
- asiatic acid
- hepatic fibrosis
- tgf
- liver
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 title claims abstract description 43
- 229940011658 asiatic acid Drugs 0.000 title claims abstract description 43
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 title claims abstract description 43
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 206010019668 Hepatic fibrosis Diseases 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 21
- 241000700159 Rattus Species 0.000 description 19
- 102000009618 Transforming Growth Factors Human genes 0.000 description 12
- 108010009583 Transforming Growth Factors Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000006180 TBST buffer Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 210000004024 hepatic stellate cell Anatomy 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 5
- 101700026522 SMAD7 Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 3
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- -1 ester glycosides Chemical class 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 208000022639 SchC6pf-Schulz-Passarge syndrome Diseases 0.000 description 1
- 208000001364 Schopf-Schulz-Passarge syndrome Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- AIDBEARHLBRLMO-UHFFFAOYSA-M sodium;dodecyl sulfate;2-morpholin-4-ylethanesulfonic acid Chemical compound [Na+].OS(=O)(=O)CCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O AIDBEARHLBRLMO-UHFFFAOYSA-M 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了积雪草酸在制备药物方面的新用途，特别是在制备抗肝纤维化药物方面的用途。研究表明，积雪草酸确实在抗肝纤维化方面有着良好的药效作用，积雪草酸确实可以用于制备抗肝纤维化方面的药物。The invention discloses the new application of asiatic acid in the preparation of medicines, in particular the application in the preparation of anti-hepatic fibrosis medicines. Studies have shown that asiatic acid does have good pharmacological effects in anti-hepatic fibrosis, and asiatic acid can indeed be used to prepare anti-hepatic fibrosis drugs.
Description
Technical field
The present invention relates to the purposes of asiatic acid aspect the preparation medicine, particularly relate to the purposes of asiatic acid aspect the preparation anti-hepatic fibrosis medicines.
Background technology
Herba Centellae is a Umbelliferae Centella plant, is distributed widely in various places on the south the Yangtze river basin.All herbal medicine.In China's Herba Centellae external and existing more than the 2000 year history of curing the disease for oral administration.It has clearing away heat-damp and promoting diuresis, the function of removing toxic substances and promoting subsidence of swelling.Be applicable to jaundice due to damp-heat, heatstroke diarrhoea, sand Stranguria stranguria with blood, carbuncle sore tumefacting virus, injury from falling down.
The chemical constituent of Herba Centellae is based on triterpenes, as pentacyclic triterpene type ester glycosides such as asiaticoside, asiaticosides.Herba Centellae also contains the triterpene acids, as asiatic acid, Madecassic acid etc.In addition, also have a spot of polyacetylene alkene class, volatile oil, vanillic acid etc. in the Herba Centellae.
Asiatic acid is a kind of known substance.Asiatic acid available from U.S. SIGMA company is the high-efficient liquid phase chromatogram technology extract, yellowish-brown powder, odorless, bitter in the mouth.Molecular formula is C
48H
78O
5, molecular weight is 488.70 dalton (D), fusing point is 325 ℃-330 ℃, and is water insoluble, is dissolved in dimethyl sulfoxine.Its molecular structural formula is shown below:
Hepatic fibrosis is the case processes of various chronic hepatopathys in the liver cirrhosis evolution, its dominant mechanism is the hepatic stellate cell activation and is converted into fibroblast, producing a large amount of is the extracellular matrix of main component with collagen fiber, the hepatic tissue structure is changed gradually, the pathological process that liver function constantly descends.The signal of transforming growth factor (TGF β) impels the relevant expression of gene of fibrosis through intracellular Smad signal transduction, the topmost hepatic fibrosis signal pathway of TGF β/Smad signal pathway, TGF β is with after hepatic stellate cell (HSC-T6) TGF beta receptor combines, make the Smad2/3 phosphorylation, and combine with Smad4 and to enter nucleus, start transcribing of liver hepatic stellate cell (HSC-T6) fibrin related gene.Smad7 is the negative feedback regulatory factor of TGF signal beta approach, can suppress the Smad2/3 phosphorylation, and then suppresses hepatic fibrosis.Under pathological conditions, the TGF signal beta continues to make the Smad2/3 phosphorylation, causes fibrin gene transcription and albumen synthetic.Process of the present invention proves: asiatic acid can suppress rats'liver sternzellen (HSC-T6) activation and transform, and alpha actin (alpha-SMA) is expressed descend.Simultaneously, process of the present invention proves: asiatic acid can suppress rats'liver sternzellen collagen protein synthesis, thereby suppresses hepatic fibrosis.Process of the present invention also proves: asiatic acid suppresses the liver collagen protein synthesis by raising the inhibitory action of Smad7 Negative feedback signal performance to TGF β/Smad signal transduction.Hepatic fibrosis is a reversible process, takes the positive therapeutic measure to preventing that liver cirrhosis from being vital in the hepatic fibrosis stage.The treatment of Western medicine anti-hepatic fibrosis at present still lacks ideal medicine.Asiatic acid is a kind of medicine of effect of anti hepatic fibrosis significantly that has.
Hepatic stellate cell accounts for 15% of all hepatocyte sums.Under the effect of liver fibrosis due factor, hepatic stellate cell is secreted a large amount of extracellular matrixs, and substrate is mainly formed by fibrin with by hepatic stellate cell activation and the fibroblast that is transformed.Rats'liver sternzellen (HSC-T6) cell line is the cell model of research hepatic fibrosis, by U.S. Friedman SL (Division of Liver Diseases, Mount SinaiSchool of Medicine, New York, USA) professor sets up and is so kind as to give.
The documents and materials report, the medicine of useful its preparation healing skin wound of the known drugs purposes of asiatic acid, treatment keloid, and preparation prevents and treats the medicine of cardiovascular disease, control cerebrovascular disease.So far, the relevant research of asiatic acid aspect anti-hepatic fibrosis both at home and abroad all lacks convictive experimental evidence and shows that asiatic acid really can anti-hepatic fibrosis.Asiatic acid is not reported so far in the purposes aspect the preparation anti-hepatic fibrosis medicines.And our invention asiatic acid is based upon on the abundant and convictive experimental evidence basis fully in the new purposes aspect the preparation anti-hepatic fibrosis medicines.
Summary of the invention
The object of the present invention is to provide the new purposes of asiatic acid aspect the preparation anti-hepatic fibrosis medicines.
The invention provides the purposes of asiatic acid aspect the preparation anti-hepatic fibrosis medicines.
For this reason, to prove by experiment:
1, asiatic acid suppresses the beta induced rats'liver sternzellen activation of TGF and transforms, and the alpha-SMA protein expression is reduced.
2, asiatic acid suppresses the beta induced rats'liver sternzellen collagen protein synthesis of TGF.
3, the mechanism of Herba Centellae inhibition collagen protein synthesis is to raise Smad7 Negative feedback signal in TGF β/Smad signal pathway.
Below be whole experiment:
The material method:
1. cell culture
HSC-T6 keeps cultivation in low-sugar type DMEM (Invitrogen) culture medium, adds 1% mycillin (Invitrogen) and 10% hyclone (Hyclone). every hole 1 * 10
4Cell 2.5ml spreads 6 well culture plates, after 24 hours, changes and contains 0.2% hyclone DMEM and cultivated 24 hours, add AA (5 μ M, 10 μ M, 20 μ M, 30 μ M) reach 2 hours, add 1ng/ml TGF β, set up each group contrast, after 24 hours from cell extraction albumen or mRNA.
2. Protein Extraction
The culture medium of each porocyte is discarded, use the 0.01M PBS of pre-cooling to wash 2 times.The every hole of six orifice plates adds 250uL RIPA cell protein lysate, rocks to make it fully cover the bottom, places 30min on ice.The composition of RIPA protein cleavage buffer is: 1%Nonidet P-40,0.1%SDS, 1mM PMSF, 0.5%sodium deoxycholate, 1mM sodium orthovanadate, 10mM sodium fluoridein PBS.The cell sleaker is scraped and is got cell, is collected in the 1.5mL Eppendorf pipe.On ice sample is carried out Ultrasonic Pulverization, 500W, 3s * 6 time, 4 ℃, the centrifugal 10min of 12000rpm get supernatant.Be stored in-70 ℃ standby.
3. Messenger RNA (mRNA) extracting
The culture medium of each porocyte is discarded, in each hole of 12 orifice plates, add the RLT lysate that 350uL contains the β 2 mercapto ethanol with PBS buffer flushing back.Jiggle in the 1.5mL centrifuge tube that makes a collection of specimens after making lysate and cell fully contacting, extract total RNA of cell according to the description of the RNeasy Mini Kit of QIAGEN company (Cat 74104).
4. polymerase chain reaction (PCR)
RT-polymerase chain reaction (RT-PCR)
The total RNA that gets quality and be 1.5ug is the synthetic first chain cDNA (being undertaken by the test kit description) of primer with Oligo (dT), reaction reagent: 10X PCR Buffer 2.0 μ L, 50mMMgCl
22.0 μ L, 10mMdNTPs 2.0 μ L, Oligo (dT)
12-181.0 μ L, Rnase Inhibitor 1.0 μ L, M-MLV0.25 μ L, H
2O 9.75 μ L, RNA 2.0 μ L, Total Volume 20 μ L. reaction conditions: 22 ℃ of 10minutes, 42 ℃ of 15minutes, 99 ℃ of 5minutes, cDNA-20 ℃ of preservation is standby.
Real-time quantitative polymerase chain reaction (Real-Time PCR)
The sequence of primer is as follows: RatSmad7F:CGCTGTACCTTCCTCCGAT
RatSmad7R：AGAAGATATCCAGGGAGGGCTCTT
Real-Time PCR reaction reagent: 2 * iQ SYBR Green Supermix, 10 μ L, H
2O 7.2 μ L, Primer-10.4 μ L, Primer-20.4 μ L, DNA 2 μ L, reaction condition: 94 ℃, 5min, cycling condition: 94 ℃ of degeneration 20s, 60 ℃ of annealing 20s, 72 ℃ are extended 42s.40 circulations of coamplification, last circulation is hatched 5min for rearmounted 72 ℃.
5. the immune marking (Western blot)
Reagent: 0.5M Tris-HCl, PH6.8,1.5M Tris-HCl PH8.8; 40%Acrylamide/BisSolution; 20 * NuPAGE MES SDS electrophoretic buffer; 20 * NuPAGE changes the film buffer; Pvdf membrane; The X-photographic film; ECL (super signal west pico stable peroxide solution); ECL plus (Lumigen PS-3Detection Reagent Solution); 4% spacer gel, 10% separation gel, the sample of total protein 20ug; Discontinuous SDS-PAGE electrophoresis 100V, 90 minutes.Then albumen is transferred to pvdf membrane, 150V, 90 minutes.TBST washes film after changeing film.To seal 60min under 5% defatted milk powder-TBST confining liquid room temperature; TBST washes film.Hatch one anti-(1: 1000 to 1: 2000) that adds suitable concn: 4 ℃ of jogs spend the night.TBST washes film: two anti-(1: 10000 to 1: 30000) and the HRP-anti-biotin two anti-(1: 5000) in conjunction with the HRP that add suitable concn are hatched: jog 60min under the room temperature.ECL or ECL plus caused pvdf membrane between two clean transparent membranes after developing 1 minute, advance the exposure of X-line and do not wait in 2 seconds-15 minutes in the darkroom.Film after the exposure carries out developing and fixing.The result is through the scanning imaging system imaging, and carries out the content of quantitative analysis of protein matter band with Image J software.
Adopt above-mentioned experimental technique gained experimental data, can draw following result and conclusion by analysis: the result:
1.TGF β increases rats'liver sternzellen type i collagen protein expression:
2.TGF the dosage of beta induced rats'liver sternzellen type i collagen protein expression is 1ng/ml, the time is 24 hours.
3. asiatic acid suppresses rats'liver sternzellen alpha-SMA protein expression:
Asiatic acid can suppress the beta induced rats'liver sternzellen alpha-SMA protein expression of TGF, and the statistical analysis difference has significance.
4. asiatic acid suppresses rats'liver sternzellen collagen protein synthesis:
It is synthetic that asiatic acid suppresses the beta induced rats'liver sternzellen type i collagen albumen of TGF, and the statistical analysis difference has significance.
5. asiatic acid raises rats'liver sternzellen Smad7mRNA Negative feedback signal:
Asiatic acid raises rats'liver sternzellen Smad7mRNA Negative feedback signal, stops the beta induced rats'liver sternzellen type i collagen albumen of TGF synthetic by Smad7.The statistical analysis difference has significance.
Conclusion:
1. asiatic acid suppresses the beta induced rats'liver sternzellen activation of TGF and transforms.
2. it is synthetic that asiatic acid suppresses the beta induced rats'liver sternzellen type i collagen albumen of TGF.
3. asiatic acid raises Smad7mRNA Negative feedback signal, stops the beta induced rats'liver sternzellen type i collagen albumen of TGF synthetic by Smad7.Reach the drug effect that suppresses hepatic fibrosis.
From above experimental result as can be known, asiatic acid has good drug action really aspect anti-hepatic fibrosis, and asiatic acid can be used to prepare the medicine of anti-hepatic fibrosis really.
The specific embodiment
Below further specify asiatic acid of the present invention in the purposes of preparation aspect the anti-hepatic fibrosis medicines with embodiment.
Embodiment 1:
Asiatic acid acts on the rats'liver sternzellen, preparation albumen specimen, and Western blot:
1.HSC-T6 cell 1 * 10
4Spread 6 orifice plates, 5%CO
237 ℃, add asiatic acid (purchasing SIGMA company) after 24 hours as for the U.S., concentration is respectively 5 μ M, 10 μ M, 20 μ M, 30 μ M add TGF β 1ng/ml after 2 hours, continue to cultivate after 24 hours, conventional method is extracted cell protein, determining the protein quantity, and-70 ℃ store for future use or directly are Western blot.
2.Western the blot method is fully with reference to Jin Dongyan, " molecular cloning experiment guide " second edition of translation such as Li Mengfeng.Proteinic acrylamide gel electrophoresis method is referring to the 880-885 page or leaf, and protein is transferred to the method for pvdf membrane referring to the 888-893 page or leaf from the SDS acrylamide gel.
3. TBST washes film behind the commentaries on classics film.To seal 60min under 5% defatted milk powder-TBST confining liquid room temperature; TBST washes film.Anti-hatching that adds suitable concn (1: 1000 to 1: 2000): 4 ℃ of jogs spend the night.TBST washes film: two anti-(1: 10000 to 1: 30000) and the HRP-anti-biotin two anti-(1: 5000) in conjunction with the HRP that add suitable concn are hatched: jog 60min under the room temperature.ECL or ECLplus caused pvdf membrane between two clean transparent membranes after developing 1 minute, advance the exposure of X-line and do not wait in 2 seconds-15 minutes in the darkroom.Film after the exposure carries out developing and fixing.The result is through the scanning imaging system imaging.
Asiatic acid acts on the rats'liver sternzellen, extracts mRNA, RT-polymerase chain reaction (RT-PCR) and real-time quantitative polymerase chain reaction (Real-Time PCR):
1. Messenger RNA (mRNA) extracting
The culture medium of each porocyte is discarded, in each hole of 12 orifice plates, add the RLT lysate that 350uL contains the β 2 mercapto ethanol with PBS buffer flushing back.Jiggle in the 1.5mL centrifuge tube that makes a collection of specimens after making lysate and cell fully contacting, extract total RNA of cell according to the description of the RNeasy MiniKit of QIAGEN company (Cat 74104).
2. RT-polymerase chain reaction (RT-PCR)
The total RNA that gets quality and be 1.5ug is the synthetic first chain cDNA (being undertaken by the test kit description) of primer with Oligo (dT), reaction reagent: 10X PCR Buffer 2.0 μ L, 50mMMgCl
22.0 μ L, 10mMdNTPs2.0 μ L, Oligo (dT)
12-181.0 μ L, Rnase Inhibitor 1.0 μ L, M-MLV0.25 μ L, H
2O 9.75 μ L, RNA 2.0 μ L, Total Volume 20 μ L. reaction conditions: 22 ℃ of 10minutes, 42 ℃ of 15minutes, 99 ℃ of 5minutes, cDNA-20 ℃ of preservation is standby.
3. real-time quantitative polymerase chain reaction (Real-Time PCR)
The sequence of primer is as follows: RatSmad7F:CGCTGTACCTTCCTCCGAT
RatSmad7R：AGAAGATATCCAGGGAGGGCTCTT
Real-Time PCR reaction reagent: 2 * iQ SYBR Green Supermix, 10 μ L, H
2O7.2 μ L, Primer-1 0.4 μ L, Primer-20.4 μ L, DNA 2 μ L, reaction condition: 94 ℃, 5min, cycling condition: 94 ℃ of degeneration 20s, 60 ℃ of annealing 20s, 72 ℃ are extended 42s.40 circulations of coamplification, last circulation is hatched 5min for rearmounted 72 ℃.
Statistical analysis:
Use the SSPS statistical software that obtaining data are carried out the homogeneity of variance analysis, the t check is carried out in contrast between group.
From above embodiment as can be known, asiatic acid has good drug action really aspect anti-hepatic fibrosis, and asiatic acid can be used to prepare the medicine of anti-hepatic fibrosis really.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610122561 CN1943579A (en) | 2006-09-30 | 2006-09-30 | Use of asiatic acid in preparing medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610122561 CN1943579A (en) | 2006-09-30 | 2006-09-30 | Use of asiatic acid in preparing medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1943579A true CN1943579A (en) | 2007-04-11 |
Family
ID=38043373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610122561 Pending CN1943579A (en) | 2006-09-30 | 2006-09-30 | Use of asiatic acid in preparing medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1943579A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102690314A (en) * | 2011-03-22 | 2012-09-26 | 上海医药工业研究院 | Amorphous asiatic acid tromethamine salt and its preparation method |
| CN101991624B (en) * | 2009-08-27 | 2013-03-27 | 上海新康制药厂 | Method for preparing total asiatic acid, asiatic acid and madecassic acid from asiatic pennywort herb and use of prepared product |
| CN104784186A (en) * | 2015-05-06 | 2015-07-22 | 中国人民解放军第二军医大学 | Application of asiatic acid in preparation of medicine for preventing hepatitis virus |
| CN116621910A (en) * | 2023-05-17 | 2023-08-22 | 厦门大学 | An artificial potassium ion transporter with anti-hepatic fibrosis activity and its preparation method and application |
-
2006
- 2006-09-30 CN CN 200610122561 patent/CN1943579A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991624B (en) * | 2009-08-27 | 2013-03-27 | 上海新康制药厂 | Method for preparing total asiatic acid, asiatic acid and madecassic acid from asiatic pennywort herb and use of prepared product |
| CN102690314A (en) * | 2011-03-22 | 2012-09-26 | 上海医药工业研究院 | Amorphous asiatic acid tromethamine salt and its preparation method |
| CN102690314B (en) * | 2011-03-22 | 2015-06-10 | 上海医药工业研究院 | Amorphous asiatic acid tromethamine salt and its preparation method |
| CN104784186A (en) * | 2015-05-06 | 2015-07-22 | 中国人民解放军第二军医大学 | Application of asiatic acid in preparation of medicine for preventing hepatitis virus |
| CN116621910A (en) * | 2023-05-17 | 2023-08-22 | 厦门大学 | An artificial potassium ion transporter with anti-hepatic fibrosis activity and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats | |
| Roger et al. | Composition of urinary calculi: Lessons from a French epidemiologic retrospective study | |
| Leite et al. | Dipotassium glycyrrhizininate improves skin wound healing by modulating inflammatory process | |
| Huang et al. | A Synthetic curcuminoid analog,(2 E, 6 E)-2, 6-bis (2-(trifluoromethyl) benzylidene) cyclohexanone, ameliorates impaired wound healing in streptozotocin-induced diabetic mice by increasing miR-146a | |
| CN1943579A (en) | Use of asiatic acid in preparing medicine | |
| Zhang et al. | Drosophila model and network pharmacology to explore novel targets and novel active components of Chinese traditional medications for treating kidney stones | |
| Chen et al. | Catalpol promotes mitochondrial biogenesis in chondrocytes | |
| Lu et al. | Quyu Shengji formula facilitates diabetic wound healing via inhibiting the expression of prostaglandin transporter | |
| CN110556158B (en) | Screening method of anti-myocardial fibrosis drug | |
| Mirastschijski et al. | Genital wound repair and scarring | |
| Luo et al. | The mRNA levels of PPARα, HIF-1α, and VEGF in the liver tissues of rats with alcoholic liver disease | |
| Park et al. | Parthenolide has negative effects on in vitro enhanced osteogenic phenotypes by inflammatory cytokine TNF-α via inhibiting JNK signaling | |
| Wu et al. | Betulin inhibits the production of inflammatory cytokines in human gingival fibroblasts and ligature-induced periodontitis | |
| Munday et al. | Bilateral pre‐auricular papillary squamous cell carcinomas associated with papillomavirus infection in a domestic cat | |
| CN109985180B (en) | Application of traditional Chinese medicine compound composition in preparation of anti-hepatic fibrosis medicine | |
| Melloni et al. | Convolvulus pluricaulis Choisy’s extraction, chemical characterization and evaluation of the potential effects on glycaemic balance in a 3T3-L1 adipocyte cell model | |
| Lee et al. | The n-Hexane, ethylacetate, and butanol fractions from Hydnocarpi Semen enhanced wound healing in a mice ulcer model | |
| CN108299537B (en) | A kind of preparation method and application of compound | |
| Li et al. | Differential neuroprotective mechanisms of rosemary and carnosic acid in cerebral ischemia-reperfusion injury | |
| Clementi et al. | Hepato-Renal Crosstalk in Acute and Chronic Disease: From Shared Pathways to Therapeutic Targets | |
| Ariño Mons | Unraveling injury and repair mechanisms in alcohol-associated liver disease: From neutrophils to organoid-based modeling | |
| Llaneras et al. | Non-healing perianal fistulas: a clinical model of tissue senescence impairing both tissue fibrosis and regenerative potential | |
| Li et al. | Clinical observation on pericardiocentesis and glucocorticoid in the treatment of tuberculous pericarditis | |
| Pitre et al. | Focal Fungal Granulomatous Interstitial Nephritis on a Background of Class II Lupus Glomerulonephritis: SA-PO032 | |
| Lee et al. | Effects of Scutellaria baicalensis Extract on Gout-Induced Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |